Pasireotide
- Generic Name
- Pasireotide
- Brand Names
- Signifor
- Drug Type
- Small Molecule
- Chemical Formula
- C58H66N10O9
- CAS Number
- 396091-73-9
- Unique Ingredient Identifier
- 98H1T17066
- Background
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
- Indication
For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
- Associated Conditions
- Acromegaly, Cushing's Disease
Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia
- Conditions
- Congenital Hyperinsulinism
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Montefiore Medical Center
- Registration Number
- NCT02835131
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
SOM230 Ectopic ACTH-producing Tumors
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Cedars-Sinai Medical Center
- Registration Number
- NCT02780882
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Pasireotide Treatment for Neuroendocrine Tumor
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT02779257
HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
- Conditions
- Pancreatic FistulaPancreatic Neoplasms
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 126
- Registration Number
- NCT02775227
- Locations
- 🇫🇮
Helsinki University Central Hospital, Helsinki, Finland
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
- Conditions
- Pituitary TumorACTH-producing Pituitary Tumour
- Interventions
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 4
- Registration Number
- NCT02749227
- Locations
- 🇺🇸
Neuroendocrine Unit and Pituitary Center, Columbia University, New York, New York, United States
Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 57
- Registration Number
- NCT02713776
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
🇫🇷Chu Albert Michallon, La Tronche, France
Pasireotide LAR and Pegvisomant Study in Acromegaly
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT02668172
- Locations
- 🇳🇱
Erasmus Medical Center, Rotterdam, South Holland, Netherlands
Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Robert Benamouzig
- Target Recruit Count
- 24
- Registration Number
- NCT02622906
- Locations
- 🇫🇷
Société Française d'Endoscopie Digestive (SFED), Paris, France
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
- Conditions
- Cluster Headache - Episodic and Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT02619617
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Treatment of Hypoglycemia Following Gastric Bypass Surgery
- Conditions
- HypoglycemiaObesitySurgery
- Interventions
- Device: Continuous glucose monitoring (CGM)Dietary Supplement: Meal tolerance test (MTT)
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT02527993
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.